⚠ Evidence warning: Clinical trials or other evidence do not support the claim that kava preserves sleep architecture and is an effective treatment for insomnia. This page keeps it as a report of what people, websites or other media say.

Kava for Sleep and Insomnia

Sleep and Insomnia — scientific infographic poster

The use of kava for sleep is closely tied to its anxiolytic effect — for a large fraction of patients with chronic insomnia, the proximate cause is stress, anxiety, and ruminative cognition that prevent sleep onset and produce middle-night awakenings. Kava is described as addressing this anxiety-driven insomnia pathway through gamma-aminobutyric acid-A allosteric modulation, with two advantages claimed over the benzodiazepine, z-drug (zolpidem, eszopiclone), and antihistamine alternatives: that it preserves rapid eye movement (REM) sleep and slow-wave (non-REM stage 3) sleep architecture rather than suppressing them — a claim whose measured evidence comes from rats — and that it does not produce next-day cognitive impairment or amnesia. The main sleep-specific clinical studies are the Lehrl 2004 trial of a standardised kava extract in sleep disturbances linked to anxiety disorders and the Wheatley 2001 open pilot study, in which the same patients took kava and then valerian; a 2015 meta-analysis of 14 herbal insomnia trials found no herb, kava included, better than placebo. This deep-dive walks through the trial literature, the sleep architecture evidence, the comparison with conventional hypnotics, kava's liver-safety record, and how kava was used in the trials.


Table of Contents

  1. The Anxiety-Insomnia Axis
  2. The Lehrl 2004 Kava Extract Trial
  3. The Wheatley 2001 Kava and Valerian Pilot Study
  4. Sleep Architecture Preservation (REM and NREM3)
  5. Kava versus Benzodiazepines for Sleep
  6. Kava versus Z-Drugs (Zolpidem, Eszopiclone)
  7. Kava versus Antihistamines (Diphenhydramine, Doxylamine)
  8. Kava versus Melatonin, Valerian, and Other Natural Sleep Aids
  9. Menopausal and Perimenopausal Insomnia
  10. How Kava Was Used in the Trials
  11. Kava and the Liver: the Regulatory Record
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Anxiety-Insomnia Axis

Chronic insomnia is overwhelmingly anxiety-driven in adults. The clinical picture is familiar: difficulty falling asleep because of ruminative cognition (work concerns, financial worries, relationship stress), repeated middle-night awakenings with the same cognitive ruminations preventing return to sleep, and early-morning awakening with sustained autonomic arousal. The conventional sleep-medicine literature distinguishes "primary insomnia" from "anxiety-related insomnia" diagnostically but the underlying neurobiology is largely shared — both involve persistent hyperarousal of the limbic system and elevated sympathetic tone, both respond to the same pharmacological targets, and both share substantial epidemiological overlap with generalized anxiety disorder.

The implication for therapy is that any agent that effectively reduces anxiety will improve sleep, and any agent that effectively improves sleep needs to address the upstream arousal rather than just sedate the patient. Sedation without anxiolysis (the profile of antihistamines and to some extent z-drugs) tends to produce next-day grogginess without restorative sleep. Anxiolysis with mild sedation (the profile of benzodiazepines and kava) tends to produce more genuinely restorative sleep.

Kava's profile fits the anxiolysis-with-mild-sedation pattern. The kavalactones produce gamma-aminobutyric acid-A-mediated reduction in limbic arousal at clinical doses, with sedative effects emerging only at the higher end of the dose range or in combination with other central nervous system (CNS) depressants. The Sarris Kava Anxiety Depression Spectrum Study (KADSS) trial (discussed in the Anxiety Relief deep-dive) reported reductions on the Hamilton Anxiety Rating Scale (HAM-A), the Beck Anxiety Inventory and the Montgomery-Asberg Depression Rating Scale; its published abstract reports no sleep outcome.

Back to Table of Contents

The Lehrl 2004 Kava Extract Trial

The most cited sleep-specific kava trial is Lehrl 2004, published in the Journal of Affective Disorders. The multicenter study randomized 61 patients with sleep disturbances associated with non-psychotic anxiety disorders, double-blind, to either a standardized kava extract (200 mg of the extract per day) or placebo for 4 weeks, and measured outcomes with the SF-B sleep questionnaire (a German sleep questionnaire), the HAM-A, the Bf-S self-rating scale of well-being and the Clinical Global Impressions (CGI) scale.

Results:

The Lehrl finding is consistent with the broader trial literature suggesting kava's sleep effect is mediated through anxiolysis rather than primary sedation — the patients who improved most on sleep also improved most on the anxiety measure, and the improvement in subjective well-being is incompatible with a heavy-sedation mechanism that would produce next-day fatigue.

The 4-week duration is a limitation; longer-term sleep efficacy and safety data are more limited. The choice of an acetonic extract (rather than aqueous noble-cultivar root extract) is another consideration that became prominent in the wake of the 2002 European hepatotoxicity controversy, but in this specific trial liver function tests showed no adverse signal.

A larger, longer 2020 trial (phase III, 16 weeks, 171 people with diagnosed generalised anxiety disorder, an aqueous extract of dried kava root standardised to 120 mg of kavalactones twice a day) found no significant difference in anxiety reduction between kava and placebo: at the end of the controlled phase 17.4% of the kava group were classified as remitted, compared with 23.8% of the placebo group (p = 0.46). Poorer memory and tremor or shakiness occurred more often in the kava group, and liver function test abnormalities were significantly more frequent in the kava group, although no participant met criteria for herb-induced liver injury. The authors concluded that this extract was not effective for diagnosed generalised anxiety disorder; the abstract reports no sleep outcome.

Back to Table of Contents

The Wheatley 2001 Kava and Valerian Pilot Study

The Wheatley 2001 study published in Phytotherapy Research was an open pilot study without a placebo group, in which the same patients took kava and then valerian in sequence; it was not a randomised comparison. 24 patients with stress-induced insomnia took kava 120 mg daily for 6 weeks. After 2 weeks off treatment, and with 5 having dropped out, 19 took valerian 600 mg daily for another 6 weeks. Stress was measured in three areas (social, personal and life-events), and insomnia in three areas (time to fall asleep, hours slept and waking mood):

The author concluded that both may be useful in the treatment of stress and insomnia, but that further studies are required to determine their relative roles. Points of difference described between the two:

For broader context on natural sleep aids see our Valerian page, Passionflower page, and Lavender page.

Back to Table of Contents

Sleep Architecture Preservation (REM and NREM3)

One of the most important pharmacological distinctions between kava and conventional sleep medications concerns sleep architecture — the specific pattern of REM (rapid eye movement) and NREM (non-REM, divided into stages N1, N2, N3) sleep cycles through the night. Polysomnography is the technique used to map this architecture in laboratory studies.

Healthy human sleep alternates approximately every 90 minutes between NREM and REM phases. Each phase has distinctive electrical signatures, distinctive functional roles, and distinctive vulnerabilities to drug interference:

Most conventional sleep medications suppress one or both of these critical phases:

No human polysomnography study of kava is indexed in PubMed; the measured evidence on kava and sleep architecture comes from rats. In a 2005 study of sleep-disturbed rats, kava extract at 300 mg/kg shortened the time to fall asleep, had no effect on total waking or non-REM sleep time, and significantly increased delta (deep-sleep) activity during non-REM sleep, whereas the benzodiazepine flunitrazepam significantly decreased delta power; the kava effect was not blocked by the benzodiazepine-site blocker flumazenil. The kava sleep effect is described as primarily anxiolytic (reducing the limbic hyperarousal that prevents sleep onset) rather than direct sedative suppression of higher cortical states. This is the main theoretical advantage claimed for kava over conventional hypnotics; it has not been measured in human sleep studies.

One proposed explanation involves gamma-aminobutyric acid-A receptor subunits. Benzodiazepines act non-selectively across α1, α2, α3, and α5 containing gamma-aminobutyric acid-A receptors, with the α1 subtype mediating both sedation and the slow-wave sleep suppression effect. The measured data do not support the idea that kavalactones act preferentially at non-α1 subtypes. A 2016 laboratory study of kavain, the major anxiolytic kavalactone, on human gamma-aminobutyric acid-A receptors expressed in frog eggs (Xenopus oocytes) found that kavain boosted all the receptor types tested, regardless of subunit make-up, with greater enhancement at the α4β2δ type than at the α1β2γ2L type. Its effect was unaffected by flumazenil, indicating that kavain does not act through the classical benzodiazepine binding site.

Back to Table of Contents

Kava versus Benzodiazepines for Sleep

Benzodiazepines (temazepam, lorazepam, clonazepam used at bedtime, alprazolam less commonly) are still widely prescribed for insomnia despite well-established harms with chronic use. Kava's profile for sleep parallels its profile for anxiety, with several specific advantages and one disadvantage in the sleep-specific use case.

Where Kava Wins for Sleep

Where Benzodiazepines Win for Sleep

Herbal practitioners describe kava as an option tried for chronic stress-related insomnia not responsive to sleep hygiene measures, before benzodiazepine therapy. For acute severe insomnia, or where a rapid reliable effect is needed, benzodiazepines remain the established prescription option.

Back to Table of Contents

Kava versus Z-Drugs (Zolpidem, Eszopiclone)

The "z-drugs" (zolpidem, zaleplon, eszopiclone, zopiclone) are non-benzodiazepine gamma-aminobutyric acid-A modulators that selectively target the α1 subunit, producing more selective sedation with somewhat less of the anxiolytic effect of classic benzodiazepines. They have largely replaced benzodiazepines as first-line prescribed hypnotics in much of the developed world.

Important distinctions versus kava:

Proponents describe kava as an alternative for people who have had a poor experience with z-drugs (whether through parasomnias, tolerance, or persistent next-day grogginess), because its mechanism and side-effect profile differ.

Back to Table of Contents

Kava versus Antihistamines (Diphenhydramine, Doxylamine)

Over-the-counter night-time products — diphenhydramine combined with acetaminophen or ibuprofen, and stand-alone night-time sleep aids — rely on first-generation antihistamines — diphenhydramine or doxylamine — for their sleep effect. These are extremely widely used, easily available, and generally considered "safe" by the lay public despite a problematic profile for chronic use.

Antihistamine sleep aids have important limitations versus kava:

Kava lacks the anticholinergic side effects of these over-the-counter antihistamines, but it carries its own liver-safety record (see Kava and the Liver below).

Back to Table of Contents

Kava versus Melatonin, Valerian, and Other Natural Sleep Aids

Within the natural-medicine sleep aid category, kava competes with melatonin, valerian, passionflower, and several others. Each has a distinctive mechanism and use case.

A 2015 systematic review and meta-analysis of 14 randomised trials, involving a total of 1602 participants with insomnia, covered four single-herb preparations: valerian, chamomile, kava and wuling. It found no statistically significant difference between any herbal medicine and placebo, or any herbal medicine and active control, for any of the thirteen measures of clinical efficacy. A similar or smaller number of adverse events per person were reported with kava, chamomile and wuling than with placebo, and a greater number with valerian.

Melatonin

Valerian

Passionflower

Lavender (Oral Lavender Oil)

Ashwagandha

For primary anxiety-related insomnia, some practitioners describe combining melatonin 0.5–1 mg at bedtime for circadian signaling with kava 120 mg kavalactones at bedtime for anxiolysis, adding valerian or ashwagandha for chronic maintenance. No trial of this combination is cited on this page.

Back to Table of Contents

Menopausal and Perimenopausal Insomnia

Insomnia is one of the most distressing symptoms of perimenopause and early menopause, with up to 60% of perimenopausal women reporting clinically significant sleep disturbance. The biology is multi-factorial: declining progesterone (which has gamma-aminobutyric acid-A modulating activity through its allopregnanolone metabolite) reduces endogenous gamma-aminobutyric acid tone, hot flashes produce direct sleep disruption, mood disturbance contributes to ruminative cognition, and circadian shifts associated with hormonal change disturb sleep timing.

Limited evidence supports kava for perimenopausal anxiety; its effect on menopausal sleep has not been measured in the trial described below. The proposed mechanism is that kava restores gamma-aminobutyric acid-A tone that has dropped with declining progesterone, addresses anxiety component of the menopausal symptom complex, and does so without the cardiovascular concerns of hormone replacement therapy or the selective serotonin reuptake inhibitor (SSRI) side effects (sexual dysfunction, gastrointestinal (GI) upset, weight gain) that affect many menopausal women on conventional therapy.

The trial literature is small. A 2003 three-month randomized, open (unblinded) study by Cagnacci et al. gave perimenopausal women calcium alone (n=34), calcium plus kava 100 mg/day (n=15) or calcium plus kava 200 mg/day (n=19). Anxiety, depression and climacteric (menopausal) scores fell on kava, but only the decline of anxiety was significantly greater than the change in the calcium-only group (P<0.009). Sleep was not measured.

The hepatotoxicity caution is particularly relevant in perimenopausal women, who may have higher baseline transaminase elevations (non-alcoholic fatty liver disease (NAFLD) prevalence rises in this age range) and who often use kava in combination with other supplements including black cohosh (also with documented hepatotoxicity concerns). The liver-injury record, and the symptoms of serious liver disease the U.S. Food and Drug Administration lists, are set out in Kava and the Liver below.

Back to Table of Contents

How Kava Was Used in the Trials

Doses and Durations in the Trials

Product Types Practitioners Describe

Sleep Dosing Described by Practitioners

What Users Describe

Interactions and Hazards

Cycling

A cycling pattern described by practitioners for chronic nightly use is 4 weeks of nightly use followed by 1 week off, repeated; others describe intermittent use (3–4 nights per week, on the worst-sleep nights) to limit chronic exposure. These patterns come from practice, not from trials.

For broader sleep management see our Sleep Hygiene page and Insomnia page.

Back to Table of Contents

Kava and the Liver: the Regulatory Record

Before 1998, according to a 2004 review, kava extracts were considered very safe alternatives to anxiety drugs. By January 2003 kava extracts had been banned in the entire European Union and Canada, and were subject to cautions and advisories by the U.S. Food and Drug Administration, as a result of 11 cases of liver failure leading to liver transplants, including four deaths. The review counted 78 cases of liver toxicity reputedly linked to kava: four probably linked to kavalactones taken alone, and another 23 potentially linked to kava but also involving other compounds with potential liver toxicity. It described kava toxicity as appearing “idiosyncratic” and the potential for drug interactions as large.

The U.S. Food and Drug Administration's consumer advisory of March 25, 2002 states that kava-containing products had been associated with liver-related injuries — including hepatitis, cirrhosis, and liver failure — in over 25 reports of adverse events in other countries, and that four patients required liver transplants. In the U.S., the agency had received a report of a previously healthy young female who required liver transplantation, as well as several reports of liver-related injuries. The advisory lists jaundice (yellowing of the skin or whites of the eyes) and brown urine as symptoms of serious liver disease, and nausea, vomiting, light-colored stools, unusual tiredness, weakness, stomach or abdominal pain, and loss of appetite as non-specific symptoms of liver disease.

In the 2020 trial of an aqueous kava root extract (171 people, 16 weeks), liver function test abnormalities were significantly more frequent in the kava group than in the placebo group, although no participant met criteria for herb-induced liver injury.

Back to Table of Contents

Key Research Papers

  1. Lehrl S (2004). Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Journal of Affective Disorders. — PubMed PMID: 14706720
  2. Wheatley D (2001). Kava and valerian in the treatment of stress-induced insomnia. Phytotherapy Research. — PubMed PMID: 11536390
  3. Cagnacci A et al. (2003). Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas. — PubMed PMID: 12590005
  4. Ernst E (2006). Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine. 13(3):205–208 — PubMed PMID: 16428031
  5. Sarris J, McIntyre E, Camfield DA (2013). Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs. 27(4):301–319 — PubMed PMID: 23653088
  6. Geier FP, Konstantinowicz T (2004). Kava treatment in patients with anxiety. Phytotherapy Research. — PubMed PMID: 15162364
  7. Gray SL et al. (2015). Cumulative use of strong anticholinergics and incident dementia. JAMA Internal Medicine. — PubMed PMID: 25621434 (context for diphenhydramine comparison)
  8. Shinomiya K, Inoue T, Utsu Y, et al. (2005). Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Psychopharmacology. 180(3):564–569 — PubMed PMID: 15700178 (rat study; no human polysomnography study of kava is indexed in PubMed)
  9. Sarris J, Moylan S, Camfield DA, et al. (2012). Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence. Evidence-Based Complementary and Alternative Medicine. 2012:809653 — PubMed PMID: 22969831
  10. Chua HC, Christensen ET, Hoestgaard-Jensen K, et al. (2016). Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One. 11(6):e0157700 — PubMed PMID: 27332705
  11. Leach MJ, Page AT (2015). Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews. 24:1–12 — PubMed PMID: 25644982
  12. Sarris J, Kavanagh DJ, Byrne G, et al. (2009). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology. 205(3):399–407 — PubMed PMID: 19430766
  13. Sarris J, Byrne GJ, Bousman CA, et al. (2020). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian and New Zealand Journal of Psychiatry. 54(3):288–297 — PubMed PMID: 31813230
  14. Clouatre DL (2004). Kava kava: examining new reports of toxicity. Toxicology Letters. 150(1):85–96 — PubMed PMID: 15068826
  15. U.S. Food and Drug Administration (2002). Consumer Advisory: Kava-Containing Dietary Supplements May be Associated With Severe Liver Injury. March 25, 2002 — FDA consumer advisory (archived copy)

PubMed Topic Searches

  1. PubMed: Kava insomnia RCTs
  2. PubMed: Kava polysomnography
  3. PubMed: Kava menopausal sleep
  4. PubMed: Natural sleep aids
  5. PubMed: GABA-A α1 and sleep

Back to Table of Contents

Connections

Back to Table of Contents